Solid dispersions containing an apoptosis-inducing agent

Abstract

A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

1 .- 49 . (canceled) 
     
     
         50 . A process for preparing a solid dispersion, comprising:
 (a) dissolving in a suitable solvent (i) an active pharmaceutical ingredient (API) comprising a compound of Formula I   
       
         
           
           
               
               
           
         
         where: 
         R 0  is halo; 
         R 1  and R 2  are H or are independently methyl or methoxy; 
         R 3  and R 4  are independently methyl or methoxy if R 1  and R 2  are H, or are H if R 1  and R 2  are independently methyl or methoxy; 
         A 1  and A 2  are each independently CH or N; 
         R 5  is C 1-4  alkyl or haloalkyl, C 1-4  alkylsulfonyl or haloalkylsulfonyl, halo, nitro or cyano; 
         X is —O— or —NH—; 
         Y is —(CH 2 ) n — where n is 0, 1, 2 or 3; and 
         R 6  is an unsubstituted or substituted 3- to 7-membered carbocyclic or heterocyclic, or is NR 7 R 8 ; 
         wherein, if R 6  is NR 7 R 8 , R 7  and R 8  are each independently H or R 9 —(CH 2 ) m — groups, no more than one of R 7  and R 8  is H, each R 9  is independently a 3- to 7-membered carbocyclic or heterocyclic ring, optionally substituted with no more than two Z 1  groups as defined below, and each m is independently 0 or 1; and 
         wherein, if R 6  is a substituted carbocyclic or heterocyclic ring, substituents thereon are no more than two Z 1  groups and/or no more than one Z 2  group, Z 1  groups being independently selected from the group consisting of (a) C 1-4  alkyl, C 2-4  alkenyl, C 1-4  alkoxy, C 1-4  alkylthio, C 1-4  alkylamino, C 1-4  alkylsulfonyl, C 1-4  alkylsulfonylamino, C 1-4  alkylcarbonyl, C 1-4  alkylcarbonylamino and C 1-4  alkylcarboxy, each optionally substituted with one or more substituents independently selected from the group consisting of halo, hydroxy, C 1-4  alkoxy, amino, C 1-4  alkylamino, di-(C 1-4  alkyl)amino and cyano, (b) halo, (e) hydroxy, (f) amino and (g) oxo groups, and Z 2  being (i) a further 3- to 6-membered carbocyclic or heterocyclic ring, optionally substituted with no more than two Z 1  groups as defined above, or (ii) NR 7 R 8  where R 7  and R 8  are as defined above; 
         or a pharmaceutically acceptable salt thereof, (ii) at least one pharmaceutically acceptable water-soluble polymeric carrier selected from the group consisting of a polyalkylene oxide, a polyacrylate, a polymethacrylate, a polyacrylamide, a vinyl acetate polymer, an oligosaccharide, a polysaccharide, and a mixture thereof, and (iii) at least one pharmaceutically acceptable surfactant; and 
         (b) removing the solvent to provide a solid matrix comprising the at least one pharmaceutically acceptable water-soluble polymeric carrier and the at least one pharmaceutically acceptable surfactant and having the compound or a pharmaceutically acceptable salt thereof dispersed in an essentially non-crystalline form therein. 
       
     
     
         51 . The process of  claim 50 , wherein the API comprises a compound of Formula I or a pharmaceutically acceptable salt thereof in parent-compound form; and the process further comprises adding a pharmaceutically acceptable acid before removing the solvent. 
     
     
         52 . The process of  claim 50 , wherein the solvent is removed under heat and/or vacuum. 
     
     
         53 . The process of  claim 50 , wherein the solvent is removed by rotary evaporation or by spray-drying. 
     
     
         54 . The process of  claim 50 , wherein the solvent comprises one or more of methanol, ethanol, acetone, tetrahydrofuran and dichloromethane. 
     
     
         55 . The process of  claim 50 , wherein the solvent comprises a dichloromethane/methanol or THF/water mixture. 
     
     
         56 . The process of  claim 50 , wherein no more than about 5% of the compound of Formula I or the pharmaceutically acceptable salt thereof in the solid matrix is crystalline as observed by X-ray diffraction analysis. 
     
     
         57 . The process of  claim 50 , wherein no more than about 2% of the compound of Formula I or the pharmaceutically acceptable salt thereof in the solid matrix is crystalline as observed by X-ray diffraction analysis. 
     
     
         58 . The process of  claim 50 , wherein no more than about 1% of the compound of Formula I or the pharmaceutically acceptable salt thereof in the solid matrix is crystalline as observed by X-ray diffraction analysis. 
     
     
         59 . The process of  claim 50 , wherein API is 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide or a pharmaceutically acceptable salt thereof. 
     
     
         60 . The process of  claim 59 , wherein the pharmaceutically acceptable surfactant is a polysorbate.